CRMA-1001

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameCRMA-1001
Drug Alias NameCRMA-1001
ClassificationCell and gene therapy > Gene therapy > Epigenetics therapyCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9 > CRISPR-dCas9
Mechanisms of ActionGene expression modulators
TargetsNot applicable
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandHong Kong
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesChroma Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesnChroma BioChroma Medicine Inc
Inactive CompaniesN/A
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A